PE99499A1 - Composicion farmaceutica para el tratamiento de la diabetes - Google Patents

Composicion farmaceutica para el tratamiento de la diabetes

Info

Publication number
PE99499A1
PE99499A1 PE1998000630A PE00063098A PE99499A1 PE 99499 A1 PE99499 A1 PE 99499A1 PE 1998000630 A PE1998000630 A PE 1998000630A PE 00063098 A PE00063098 A PE 00063098A PE 99499 A1 PE99499 A1 PE 99499A1
Authority
PE
Peru
Prior art keywords
treatment
inahibor
diabetes
pharmaceutical composition
gautia
Prior art date
Application number
PE1998000630A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Alistair Smith
Robin Edwin Buckingham
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE99499A1 publication Critical patent/PE99499A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
PE1998000630A 1997-07-18 1998-07-16 Composicion farmaceutica para el tratamiento de la diabetes PE99499A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
PE99499A1 true PE99499A1 (es) 1999-12-18

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000630A PE99499A1 (es) 1997-07-18 1998-07-16 Composicion farmaceutica para el tratamiento de la diabetes

Country Status (27)

Country Link
EP (1) EP1001784A1 (sk)
JP (1) JP2001510160A (sk)
KR (1) KR20010021952A (sk)
CN (1) CN1263467A (sk)
AP (1) AP2000001735A0 (sk)
AR (2) AR016350A1 (sk)
AU (1) AU8449098A (sk)
BG (1) BG104062A (sk)
BR (1) BR9810292A (sk)
CA (1) CA2297133A1 (sk)
CO (1) CO4940489A1 (sk)
DZ (1) DZ2563A1 (sk)
EA (1) EA200000140A1 (sk)
GB (1) GB9715298D0 (sk)
HU (1) HUP0003626A3 (sk)
ID (1) ID23804A (sk)
IL (1) IL133907A0 (sk)
MA (1) MA24608A1 (sk)
NO (1) NO20000230D0 (sk)
OA (1) OA11312A (sk)
PE (1) PE99499A1 (sk)
PL (1) PL338140A1 (sk)
SK (1) SK612000A3 (sk)
TR (1) TR200000133T2 (sk)
UY (1) UY25101A1 (sk)
WO (1) WO1999003478A1 (sk)
ZA (1) ZA986364B (sk)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP1849475A1 (en) 1999-06-21 2007-10-31 Eli Lilly & Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
DE122008000018I1 (de) * 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US20030040490A1 (en) * 2000-02-24 2003-02-27 Yasuo Sugiyama Drugs containing combined active ingredients
JP4917712B2 (ja) * 2000-02-24 2012-04-18 武田薬品工業株式会社 併用医薬
MXPA03006217A (es) 2001-01-12 2004-10-15 Sun Pharmaceutical Ind Ltd Sistema de administracion espaciada de farmacos.
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
CN1874774B (zh) 2003-10-31 2011-04-13 武田药品工业株式会社 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂
CN101103993B (zh) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 降糖药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003724A1 (en) * 1991-08-26 1993-03-04 The Upjohn Company Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
JP2001510160A (ja) 2001-07-31
BR9810292A (pt) 2000-09-19
AU8449098A (en) 1999-02-10
AR016350A1 (es) 2001-07-04
CA2297133A1 (en) 1999-01-28
PL338140A1 (en) 2000-09-25
AR019724A2 (es) 2002-03-13
KR20010021952A (ko) 2001-03-15
IL133907A0 (en) 2001-04-30
ZA986364B (en) 2000-01-17
AP2000001735A0 (en) 2000-01-16
GB9715298D0 (en) 1997-09-24
BG104062A (en) 2000-11-30
EA200000140A1 (ru) 2000-06-26
HUP0003626A3 (en) 2001-12-28
UY25101A1 (es) 2000-12-29
NO20000230L (no) 2000-01-17
CO4940489A1 (es) 2000-07-24
DZ2563A1 (fr) 2003-02-15
ID23804A (id) 2000-05-11
TR200000133T2 (tr) 2000-09-21
HUP0003626A2 (hu) 2001-05-28
CN1263467A (zh) 2000-08-16
OA11312A (en) 2003-10-24
EP1001784A1 (en) 2000-05-24
SK612000A3 (en) 2000-07-11
WO1999003478A1 (en) 1999-01-28
NO20000230D0 (no) 2000-01-17
MA24608A1 (fr) 1999-04-01

Similar Documents

Publication Publication Date Title
PE83199A1 (es) Composicion farmaceutica de tiazolidinadiona y biguanida para el tratamiento de la diabetes
PE99599A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
AR057970A2 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
ES2071339T3 (es) Agentes hipoglicemicos e hipocolesterolemicos de oxazolidindiona.
PE104499A1 (es) Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes
EP1593379A3 (en) Uses of PPAR-gamma agonists in neutrophil-induced diseases
PE99499A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
AR046210A1 (es) Preparacion solida
PE99799A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
PE89199A1 (es) Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
PE20030277A1 (es) Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa
EA200300005A1 (ru) Соль тиазолидиндиона для лечения сахарного диабета
PT1446404E (pt) Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos
EA200300423A1 (ru) Производное тиазолидиндиона и его применение в качестве противодиабетического лекарственного средства
ECSP034467A (es) Farmaceutico novedoso
EA200300004A1 (ru) Гидроиодид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона в качестве фармацевтического препарата
CO5150180A1 (es) Nueva composicion y uso liberacion modificada
ECSP982534A (es) Nuevo metodo de tratamiento
ECSP982542A (es) Nuevo metodo de tratamiento iii
ECSP982535A (es) Nuevo metodo de tratamiento (i)
TH36758A (th) กรรมวิธีในการรักษาโรคเบาหวานด้วยไธอะโซลิดีนไดโอนและเมทฟอร์มิน

Legal Events

Date Code Title Description
FC Refusal